An improved synthesis of [18F]VAT and its precursor

Abstract

The vesicular acetylcholine transporter (VAChT) in the brain is an important presynaptic cholinergic biomarker, and neuroimaging studies of VAChT may provide in vivo information about psychiatric and neurologic conditions including Alzheimer's disease that are not accessible by other methods. The 18F‐labeled radiotracer, ((‐)‐(1‐(‐8‐(2‐[18F]fluoroethoxy)‐3‐hydroxy‐1,2,3,4‐tetrahydronaphthalen‐2‐yl)piperidin‐4‐yl)(4‐fluorophenyl)‐methanone ([18F]VAT, 1), was reported as a selective and high affinity ligand for the in vivo imaging of VAChT. The synthesis of [18F]VAT has been reported in a two‐step procedure with total 140 min, which includes preparation of 2‐[18F]fluoroethyltosylate and alkylation of benzovesamicol (‐)‐5 precursor with this radiosynthon using two different automated production modules consecutively. A multiple step synthetic route was employed for the synthesis of stereospecific precursor benzovesamicol (‐)‐5, which is difficult to be adapted for scale‐up. To make the production of this tracer more amenable for clinical imaging, we present an improved total synthesis protocol to attain [18F]VAT: (1) a tosylethoxy group being pre‐installed tosylate precursor (‐)‐8 is synthesized to render a simple one‐step radiofluorination under mild conditions; (2) The key optically active intermediate benzovesamicol (‐)‐5 was obtained via the regio‐ and enantio‐enriched ring‐opening amination of meso‐epoxide 3 with 4‐phenylpiperidine derivative 2 under catalysis of a chiral salenCo(III) catalyst 4b, which dramatically simplifies the synthetic route of the tosylate precursor (‐)‐8. [18F]VAT 1 was prepared within ~65 min with desired chemical and radiochemical purities, via a fully automated procedure, using a commercial PET tracer production module. The final drug product was obtained as a sterile, pyrogen‐free solution that conforms United States Pharmacopeia (USP) <823> requirements.